Evidence map›Paper›PMID 40813475›Full record

ArticleCardiovascular and interventional radiology2025

Segmental Yttrium-90 Radioembolization with Day-of-Calibration Resin Microspheres: Durable Transarterial Ablation for Solitary Hepatocellular Carcinoma.

Adam D Talenfeld, Robert Peng, Anna Sophia McKenney, Benjamin Cobb, Komal A Chughtai, Andrea Siobhan Kierans, Preethi Guniganti, Christopher Song, Mohamed M Soliman, Steven Pan and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Adam D TalenfeldDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA. adt9010@med.cornell.edu.ORCID http://orcid.org/0000-0002-3029-720X
Robert PengDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA.
Anna Sophia McKenneyDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA.
Benjamin CobbImaging Data Analysis and Evaluation & Analytics Laboratory (IDEAL), Department of Radiology, NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, USA.
Komal A ChughtaiDivision of Abdominal Imaging, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA.
Andrea Siobhan KieransDivision of Abdominal Imaging, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA.
Preethi GunigantiDivision of Abdominal Imaging, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA.
Christopher SongHackensack Radiology, Hackensack, NJ, USA.
Mohamed M SolimanNewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, USA.
Steven PanMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Alan WuDivision of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Arindam RoyChoudhuryDivision of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Benjamin J MayDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA.
Brian M CurrieDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA.
Anuj MalhotraDivision of Interventional Radiology, NYU Langone Radiology, NYU Langone Hospital, Long Island, Mineola, NY, USA.
William F BrowneDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA.
Resmi A CharalelDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA.
Nicole C PanarelliDivision of Gastrointestinal and Liver Pathology, Department of Pathology and Laboratory Medicine, Weill Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA.
Kyungmouk Steve LeeDivision of Interventional Radiology, Department of Radiology/Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, P-501, New York, NY, 10065, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSeveral recent studies report safety and efficacy of resin yttrium-90 radiation segmentectomy for localized hepatocellular carcinoma. Data informing tumor dose, angiosome dose, and spheres/mL required for ablative-intent resin radioembolization are incomplete. The safety, efficacy, dosimetry, and explant pathology of radiation segmentectomy with day-of calibration (DOC) spheres are reported. MATERIALS AND

methodsPatients were identified at a tertiary care institution who received radiation segmentectomy with DOC resin during a 10-year period. Post-Y90 dosimetry was performed with Medical Image Merge (MIM) Software. Imaging response, 30-day toxicities, explant pathology, duration of response, and overall survival were analyzed. Associations between dosimetric variables and durable response were tested with receiver operator characteristic, Wilcoxon, and odds ratio analyses.

resultsTwenty tumors in 20 patients were treated, median size 2.6 [range 1.4-6.3] cm. Fifteen patients (75%) were male; median age 68 [range 48-88] years. Seventeen patients (85%) had Child A cirrhosis, 12 from hepatitis C; 15/20 were AlBi grade 2. Sixteen single-vessel and four double-vessel (split dose) treatments reached stasis in 17/24 (71%) infusions. Median tumor and angiosome dose were 263 [range 83-649] and 139 [31-392]. Median lowest dose to any portion of a treated tumor was 147 [29-299] Gy. Median tumor sphere concentration was 79 k [23-206 k] spheres/mL. Local modified REsponse Evaluation Criteria in Solid Tumors (mRECIST) response rates were 18 (90%) complete (16 durable), one partial response, and one stable disease. Two patients experienced adverse events: one at grade 3 and the other at grade 2. Median follow-up was 20 [range 4-126] months. Median duration of response was 47 months. Median overall survival was > / = 94 months both with and without censoring patients at transplant. All six explants demonstrated complete pathologic necrosis. Smaller tumor volume was associated with durable complete response (AUC 0.96), as was infusion to stasis (OR 18 [95% CI 1.19, 271]). Smaller tumor volume and lower angiosome dose were associated with stasis (p = 0.013, 0.035).

conclusionDay-of calibration resin segmentectomy treating to stasis is safe and may yield highly durable ablative outcomes for HCC under 3 cm diameter at lower doses than recommended for glass or pre-calibrated resin Y90. Use of more spheres or higher dose targets is likely warranted for larger tumors.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsYttrium RadioisotopesAgedAged, 80 and overFemaleHumansMaleMicrospheresMiddle AgedRadiopharmaceuticalsRadiotherapy DosageRetrospective StudiesTreatment OutcomeRadiopharmaceuticalsYttrium-90Yttrium RadioisotopesHCChepatocellular carcinomaradiation dosimetryradiation segmentectomy,radioembolizationresinTAREvoxel-based dosimetryY90yttrium-90

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.